These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16140593)

  • 1. A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life.
    Kerr MP; Baker GA; Brodie MJ
    Epilepsy Behav; 2005 Nov; 7(3):472-80. PubMed ID: 16140593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topiramate: a review of its use in childhood epilepsy.
    Ormrod D; McClellan K
    Paediatr Drugs; 2001; 3(4):293-319. PubMed ID: 11354701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topiramate in patients with epilepsy and intellectual disability.
    Martin P; Schreiner A; Rettig K; Schäuble B
    Epilepsy Behav; 2009 Mar; 14(3):496-502. PubMed ID: 19162230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy.
    Sharief M; Viteri C; Ben-Menachem E; Weber M; Reife R; Pledger G; Karim R
    Epilepsy Res; 1996 Nov; 25(3):217-24. PubMed ID: 8956919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.
    Sachdeo RC; Glauser TA; Ritter F; Reife R; Lim P; Pledger G
    Neurology; 1999 Jun; 52(9):1882-7. PubMed ID: 10371538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topiramate in migraine prevention: a double-blind, placebo-controlled study.
    Storey JR; Calder CS; Hart DE; Potter DL
    Headache; 2001; 41(10):968-75. PubMed ID: 11903524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group.
    Privitera M; Fincham R; Penry J; Reife R; Kramer L; Pledger G; Karim R
    Neurology; 1996 Jun; 46(6):1678-83. PubMed ID: 8649569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term assessment of topiramate for epilepsy: an open-label, single-arm, multicentre, prospective study in a naturalistic setting.
    Hufnagel A; Kowalik A; Rettig K; Schreiner A; Schäuble B;
    Clin Drug Investig; 2011 Nov; 31(11):779-90. PubMed ID: 21967069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy.
    Gilliam FG; Veloso F; Bomhof MA; Gazda SK; Biton V; Ter Bruggen JP; Neto W; Bailey C; Pledger G; Wu SC
    Neurology; 2003 Jan; 60(2):196-202. PubMed ID: 12552030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topiramate add-on for drug-resistant partial epilepsy.
    Pulman J; Jette N; Dykeman J; Hemming K; Hutton JL; Marson AG
    Cochrane Database Syst Rev; 2014 Feb; (2):CD001417. PubMed ID: 24570033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures.
    Chung SS; Hogan RE; Blatt I; Lawson P B; Nguyen H; Clark AM; Anders B; Halvorsen MB;
    Epilepsy Behav; 2016 Jun; 59():13-20. PubMed ID: 27084978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pooled analysis of adjunctive topiramate in refractory partial epilepsy.
    Peeters K; Adriaenssen I; Wapenaar R; Neto W; Pledger G
    Acta Neurol Scand; 2003 Jul; 108(1):9-15. PubMed ID: 12807387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, outpatient, open-label study to evaluate the dosing, effectiveness, and safety of topiramate as monotherapy in the treatment of epilepsy in clinical practice.
    Sankar R; Ramsay E; McKay A; Hulihan J; Wiegand F;
    Epilepsy Behav; 2009 Aug; 15(4):506-12. PubMed ID: 19643672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group.
    Faught E; Wilder BJ; Ramsay RE; Reife RA; Kramer LD; Pledger GW; Karim RM
    Neurology; 1996 Jun; 46(6):1684-90. PubMed ID: 8649570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy.
    Arroyo S; Dodson WE; Privitera MD; Glauser TA; Naritoku DK; Dlugos DJ; Wang S; Schwabe SK; Twyman RE;
    Acta Neurol Scand; 2005 Oct; 112(4):214-22. PubMed ID: 16146489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group.
    Elterman RD; Glauser TA; Wyllie E; Reife R; Wu SC; Pledger G
    Neurology; 1999 Apr; 52(7):1338-44. PubMed ID: 10227615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of topiramate in childhood generalized seizure disorders.
    Wheless JW
    J Child Neurol; 2000; 15 Suppl 1():S7-13. PubMed ID: 11218056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Korean Topiramate Study Group.
    Epilepsia; 1999 Dec; 40(12):1767-74. PubMed ID: 10612342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topiramate titration to response: analysis of individualized therapy study (TRAITS).
    Dodson WE; Kamin M; Kraut L; Olson WH; Wu SC
    Ann Pharmacother; 2003 May; 37(5):615-20. PubMed ID: 12708932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures.
    Ben-Menachem E; Henriksen O; Dam M; Mikkelsen M; Schmidt D; Reid S; Reife R; Kramer L; Pledger G; Karim R
    Epilepsia; 1996 Jun; 37(6):539-43. PubMed ID: 8641230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.